Место «респираторных» фторхинолонов в лечениивнебольничной пневмонии у взрослых

1. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М.: OOO «Издательский дом «М-Вести», 2006.
2. Bariffi F, Sanduzzi A, Ponticiella A. Epidemiology of lower respiratory tract infections. J Chemother 1995; 7: 263–76.
3. Barlow GD, Lamping DL, Davey PG et al. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians and policy-makers. Clin Inf Dis 2003; 3: 476–88.
4. Marrie TJ. Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults. 2008. www.uptodate.com
5. Amsden GW, Amankwa K. Pneumococcal resistance: The treatment challenge. Ann Pharmacother 2001; 35 (4): 480–8.
6. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. биол. и антимикроб. химиотер. 2006; 1 (8): 33–47.
7. Hoban DJ, Doern GV, Fluit AC et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumonia, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis 2001; 32 (Suppl. 2): S81–93.
8. Shams E, Evans M. Guide to Selection of Fluoroquinolones in Patients with Lower Respiratory Tract Infections. Drugs 2005; 65 (7): 949–91.
9. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000; 46: 17–24.
10. Anderson MI, MacGowan AP. Development of the quinolones. JАС 2003; 51 Suppl. S1: 1–11.
11. Emmerson AM, Jones AM. The quinolones: decades of development and use. JАC 2003; 51 Suppl. S1: 13–20.
12. Nord C, Edlund C. Susceptibility of anaerobic bacteria to BAY 12–8039, a new methoxyquinolone. Clin Microb Infection 1997; 3 (Suppl. 2): 285.
13. MacGowan A, Bowker K, Holt H et al. BAY 12-8039, a new 8-methoxyquinolone: comparative in vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother 1997; 40: 503–9.
14. Hoban DJ, Bouchillon SK, Johnson JL et al. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn Microb Infect Dis 2001; 40: 51–7.
15. Koeth LM, Jacobs MR, Bajaksouzian S et al. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Unated States in 1999–2000. Intern J Antimicrob Agents 2002; 19: 33–7.
16. Davis SL, Neuhauser MM, McKinnon. Quinolones. www.antimicrobe.org
17. Zanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001; 1: 459–63.
18. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired pneumonia in Adults. Clin Infect Dis 2007; 44: 27–72.
19. Jones M, Draghi D, Thornsberry C, Sahm D. A current perspective on S. pneumoniae and H.influenzae resistance trends in Europe: GLOBAL Surveillance Study, 2005. Proceedings of 16th ECCMID, 2006. Abstr. 1629.
20. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicology Letters 2002; 127: 269–77.
21. Jannini P, Mandel L. An updated safety profile of moxifloxacin. J Chemoter 2002; 14 (2): 29–34.
22. Morganroth J, DiMarco J, Anzueto A et al. A randomized trial comparing the cardiac rhytm safety of moxifloxacin vs levofljxacin in elderly patients yospitalized with Community-Acguired pneumonia. Chest 2005; 5 (128): 3398–406.
23. Ball P, Mandell L, Patou G et al. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004; 23: 421–9.
24. Ferrara A. A brief review of moxifloxacin in the treatment of elderly patients with Community-Acguired pneumonia. Clin Inter IN aging 2007; 2 (2): 179–87.
25. Fogarty S, Grossman C, Williams S et al. Efficacy and safety of moxifloxacin vs. clarithromycin for Community-Acguired pneumonia. Effect Med 1999; 16: 748–63.
26. Patel T, Pearl J, Williams S et al. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with Community-Acguired pneumonia. Respir Med 2000, 94: 97–105.
27. Hoeffcen G, Meyer H, Winter J et al. Efficacy and safety of two oral day moxifloxacin regimens to oral clarithromycin in the treatment of patients with Community-Acguired pneumonia. Respir Med 2001; 95: 553–64.
28. Petitpretz P, Arvis P, Marel M et al. Oral moxifloxacin vs. high-dosade amoxicillin in the treatment of mild to moderate, Community-Acguired subjected pnumococcal pneumonia in aduls. Chest 2001, 119: 185–95.
29. Finch R, Schurmann D, Collins O et al. Randomized controlled trial of seqentual i.v. and oral moxifloxacin compared with seqentual i.v. and oral co–amoxiclav with oe without clarithromycin in patients with Community-Acguired pneumonia reguiring initial parenteral treatment. Antimicrob Agents Chemother 2002, 46: 1746–54.
30. Torres A, Muir J, Corris P et al. Effectivenes of oral moxifloxacin in standart first-line therapy in Community-Acguired pneumonia. Eur respir J 2003; 21: 135–43.
31. Jardim J, Rico J et al. A comparison of moxifloxacin and amoxicillin in the treatment of Community-Acguired pneumonia in Latin America: results of a multicenter clinical trial. Arch Bronconeumol 2003, 39: 387–93.
32. Katz E, Larsen L., Fogarty C et al. Safety and efficacy of seqentual i.v. to p.o. moxifloxacin versus conventional combination for the treatment of Community-Acguired pneumonia in patients reguiring initial i.v. therapy. J Emerg Med 2004; 27: 395–405.
33. Portier H, Brabilla C, Carre M et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxitromycin for nonsevere Community-Acguired pneumonia in aduls with risk factors. Eur J Clin Microbiol Infect Dis 2005; 24: 367–76.
34. Fogarty C, Torres A, Choudhri S et al. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant S.pneumoniae in Community-Acguired pneumonia. Int J Clin Pract 2005; 59: 1253–9.
35. Welte T, Petermann W, Schurmann D et al. Treatment with seqentual i.v. or oral moxifloxacin was associated with faster clinical improvent than was standart therapy for hospitalized with Community-Acguired pneumonia. Clin Effect Dis 2005; 41: 1697–705.
36. Anzueto A, Niederman M, Pearle J et al. Community-Acguired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin. Clin Effect Dis 2006; 42: 73–81.
37. Синопальников А.И., Андреева И.В., Стецюк О.У. Пневмонии в домах престарелых: современный взгляд на проблему. Клин. микробиол. и антимикроб. химиотер. 2007; 9 (1): 4–19.
38. Chen DK, McGeer A, de Azavedo JC et al. Decreased susceptibility of Streptococcus pneumoniae to fluorquinolones in Canada. Canadian Bacterial Surveillance Network. N Eng J Med 1999; 341: 233–39.
39. Eisen S, Miller D, Woodward R et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–4.